What GLP-1 actually is
GLP-1 is a peptide hormone, a short chain of 30 amino acids cleaved from a larger precursor protein called proglucagon. Proglucagon is a master gene: depending on where it's expressed, it gets cut into different products. In the pancreas, it becomes glucagon (the hormone that raises blood sugar). In intestinal L-cells and certain brainstem neurons, it becomes GLP-1, GLP-2, and other peptides.
This matters because GLP-1 is fundamentally a nutrient-sensing hormone. The body releases it when food arrives in the lower gut, and the message it sends, in chemical terms, is "carbohydrate and fat have arrived; coordinate the response."
The orchestration that follows is remarkable. Insulin gets released to handle the glucose. Glucagon gets suppressed so the liver doesn't add more sugar to the bloodstream at the wrong moment. Gastric emptying slows so the next wave of nutrients arrives gradually. Satiety circuits in the brain are activated to stop eating. Inflammation and oxidative stress signaling are dampened. Heart rate and blood pressure shift slightly. Within minutes, the entire metabolic system is harmonized for the meal.
Pharmacologically, what GLP-1 receptor agonists like semaglutide do is borrow this orchestration and amplify it, turning a brief, post-meal signal into a continuous low-level activation across the whole receptor network.
L-cells and meal-triggered release
L-cells are specialized hormone-secreting cells embedded in the lining of your distal small intestine and colon. They are densest in the ileum and ascending colon. Each L-cell has microvilli on its luminal (gut-facing) surface that taste passing nutrients, particularly carbohydrates and fats, and trigger GLP-1 release accordingly.
Native GLP-1 secretion is brief. After a meal, levels rise sharply within 15-30 minutes, peak around 60-90 minutes, and decline back toward baseline. The half-life of native GLP-1 is around 2 minutes, because the body produces an enzyme called dipeptidyl peptidase-4 (DPP-4) whose specific job is to chop GLP-1 in half and inactivate it. This rapid clearance is by design: a sustained GLP-1 signal would dysregulate normal feeding rhythms.
That same rapid clearance, however, is precisely what made native GLP-1 useless as a medication. To turn it into a drug, scientists had to redesign the molecule to resist DPP-4. That redesign is the story of semaglutide and tirzepatide.
The receptor itself
The GLP-1 receptor (GLP-1R) is a class B G-protein-coupled receptor (GPCR). Translated: it's a protein that snakes through the cell membrane seven times, with a binding pocket on the outside and signaling machinery on the inside. When GLP-1 (or a GLP-1 mimetic) binds the outer pocket, the receptor changes shape and activates G-proteins on the inner side. Those G-proteins then trigger downstream signaling cascades that ultimately affect what the cell does.
Two key downstream pathways activate immediately:
- cAMP/PKA pathway, raises intracellular cyclic AMP, activates protein kinase A, drives gene transcription and protein activation. This is the dominant pathway in pancreatic beta cells (insulin release) and brain satiety neurons.
- β-arrestin pathway, modulates receptor desensitization and traffics other signaling effects. This pathway is part of why long-term receptor exposure can blunt effect over time, but also part of why some downstream protective effects (cardiovascular, neuroprotective) are sustained.
The balance between these two pathways, called "biased signaling", is part of why different GLP-1 analogs have somewhat different clinical profiles. Semaglutide is biased toward cAMP signaling, which favors metabolic effects. Engineering of future generations of these drugs explicitly targets which pathway gets activated more.
Where the receptor lives
This is where most people misunderstand GLP-1 drugs. The receptor isn't just in the pancreas. It's distributed across many tissues, and that distribution explains the breadth of effects.
| Tissue | What GLP-1 activation does there |
|---|---|
| Pancreatic beta cells | Stimulates glucose-dependent insulin release; preserves beta-cell mass |
| Pancreatic alpha cells | Suppresses glucagon (so liver doesn't dump glucose) |
| Hypothalamus (arcuate, PVN) | Activates POMC neurons, suppresses NPY/AgRP, reduces appetite |
| Brainstem (NTS, area postrema) | Reduces meal size; the "satiety" signal |
| Hippocampus, cortex | Neuroprotective, may improve cognition; under study for Alzheimer's |
| Reward circuits (VTA, nucleus accumbens) | Reduces food cravings, alcohol cravings, possibly other addictive behaviors |
| Stomach | Slows gastric emptying (the source of nausea side effect) |
| Heart and vessels | Improves endothelial function; reduces inflammation in vessel wall |
| Kidney | Protective against diabetic nephropathy; reduces albuminuria |
| Immune cells (macrophages, T-cells) | Anti-inflammatory effects, lower cytokines |
| Bone | Mixed: some studies suggest GLP-1R activation may modestly support bone |
| Liver | No direct receptor, but indirect effect on hepatic fat via insulin sensitization |
The pattern matters: this is not a drug that does one thing. It's a drug that taps into a master metabolic-coordination signal that the body already uses, and amplifies it across many systems simultaneously.
Downstream signaling and physiology
When semaglutide or tirzepatide binds the GLP-1R in each tissue, the downstream effect depends on what that tissue does. In a beta cell, the cAMP pathway closes potassium channels, depolarizes the cell, opens calcium channels, and triggers insulin granule fusion with the membrane, all glucose-dependent (which is why these drugs don't typically cause low blood sugar in non-diabetics). In a hypothalamic POMC neuron, the same cAMP pathway alters firing patterns and gene expression of appetite-regulating peptides. In a vascular endothelial cell, cAMP signaling activates eNOS (nitric oxide synthase) and reduces inflammatory transcription.
The fact that one signal can have so many tissue-specific effects is GPCR biology in general. The body uses about 800 different GPCRs to manage almost every aspect of physiology, and the same receptor in different cell types produces different effects because each cell type has different downstream machinery and different gene expression patterns wired to that signal.
Why semaglutide and tirzepatide work as drugs
To make GLP-1 useful as a medication, scientists modified the native peptide in three ways:
- Resist DPP-4 cleavage. The amino acid at position 8 of native GLP-1 is what DPP-4 recognizes for cleavage. By substituting that amino acid (semaglutide uses an α-aminoisobutyric acid replacement), the molecule becomes invisible to DPP-4.
- Bind albumin. A fatty acid side chain is attached to the peptide. This fatty acid binds to albumin, the most abundant protein in blood plasma. Albumin-bound molecules are protected from kidney filtration and liver clearance. The molecule rides around in circulation, gradually releasing free drug to bind GLP-1 receptors.
- Maintain receptor binding. The modifications must not destroy the parts of GLP-1 that fit into the receptor binding pocket. The result is a peptide that activates GLP-1R as well or better than native GLP-1, with a vastly extended duration of action.
Native GLP-1 half-life: ~2 minutes. Semaglutide half-life: ~165 hours (about 7 days). That's the entire engineering story of why a once-weekly injection works.
Compounded versions of semaglutide produced by 503A pharmacies use the same molecular structure as the brand-name product. The peptide sequence and modifications are identical, what differs is the manufacturer and pricing structure. Brand-name vs. compounded comparison covers the regulatory and quality-control framework.
What tirzepatide adds: GIP receptor activity
Tirzepatide is a "twincretin", a single molecule engineered to activate two receptors: GLP-1R and GIPR (glucose-dependent insulinotropic polypeptide receptor). GIP is the other major incretin hormone, also released after meals, also affecting insulin release and metabolism.
The GIP receptor is expressed in adipose tissue, brain, bone, and pancreas. Adding GIP activation to GLP-1 activation produces synergistic effects: more weight loss, more glucose control, and possibly better cardiovascular and metabolic outcomes than GLP-1 alone. In head-to-head trials (SURPASS-2), tirzepatide produced significantly greater weight loss and HbA1c reduction than semaglutide at comparable doses.
The trade-off: more receptor activation may mean more side effects in some patients, particularly GI nausea early in dose escalation. covers when each is the right choice.
Why the body-wide effects make biological sense
If you understand the receptor distribution above, the breadth of clinical effects stops being surprising:
- Cardiovascular benefit (reduced MACE in trials): direct vascular endothelial effects + indirect from improved metabolic state
- Kidney protection (reduced albuminuria, slower CKD progression): direct renal GLP-1R signaling + reduced glycemic and inflammatory load
- Mood and cognition (improved depression scores in some studies): brain GLP-1R activation + neuroinflammation reduction
- Reduced food cravings, alcohol cravings, possibly nicotine and other addictive behaviors: reward circuit GLP-1R activation
- Lower inflammation markers (hs-CRP, IL-6 reductions in trials): immune cell GLP-1R activation
- Improved sleep apnea (substantial AHI reduction in SURMOUNT-OSA trial): weight loss + airway inflammation reduction
- Reduced liver fat (NAFLD/MASH studies): metabolic improvement + indirect effects
This is what people miss when they think of GLP-1 drugs as "weight loss medications." The weight loss is one downstream effect of activating a master metabolic-coordination receptor that lives across most major organ systems.
Half-life, dosing, and steady-state
Because semaglutide has a half-life of ~165 hours and tirzepatide ~120 hours (about 5 days), once-weekly injection produces relatively stable plasma levels, with a peak at 1-3 days post-injection and a trough just before the next dose. Steady-state takes about 4-5 weeks to reach.
This is why dose escalation is gradual. The body needs time at each dose to adapt, particularly the gut motility and central satiety pathways, which produce most of the early side effects. Pushing dose faster than steady-state biology allows tends to amplify nausea and tolerability problems without producing faster weight loss.
The clinical pearl: Once you understand that GLP-1R is expressed across the brain, gut, heart, kidney, and immune system, not just the pancreas, almost every other thing about these drugs makes sense. The mood effects, the inflammation effects, the cardiovascular protection, the cravings reduction. None of it is mysterious. It's all downstream of a peptide hormone receptor that the body already uses to coordinate metabolic state across systems.
Bottom line
GLP-1 receptor agonists work because the receptor lives in many places. Semaglutide and tirzepatide are protein engineering successes, redesigned versions of a natural peptide hormone, modified to resist breakdown and bind albumin so they last days instead of minutes. Once-weekly dosing produces continuous receptor activation that amplifies the body's normal post-meal coordination signal across the brain, gut, heart, kidney, and immune system.
The clinical effects, weight loss, glycemic control, cardiovascular benefit, kidney protection, reduced cravings, improved metabolic markers, aren't separate effects. They're all downstream of the same receptor activation in different tissues. Understanding the receptor biology is the cleanest way to make sense of why these drugs do what they do.